Home › NDC Lookup › Ingredients › Olmesartan Medoxomil › 50090-4451-01
⚪image loading
(from DailyMed)

Olmesartan Medoxomil 40 mg Tablet, Film Coated, 90-count — NDC 50090-4451-1 (Billing 50090-4451-01)

by A-S Medication Solutions · 90 TABLET, FILM COATED in 1 BOTTLE

This is a package of 90 tablets of Olmesartan Medoxomil 40 mg Tablet, Film Coated from A-S Medication Solutions, marketed since May 2017 and currently FDA-listed.

NDC 50090-4451-01
🏷️ FDA NDC (as labeled) 50090-4451-1 billing pads the package segment with a zero
This package
Contains90-count Pack sizes2 compare ↓
Also priced by: Part D plans $0.2000/unit — full pricing hub ↓
Product page 50090-4451-00 Also comes in: 30 tablets 50090-4451-0
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 50090-4451-1 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
50090 labeler · 4451 product · 1 package
Package marketed since
Aug 5, 2019
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 5009044511 4
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 50090-4451-1
Product NDC 50090-4451
11-digit billing NDC 50090445101
Application # ANDA203281
SPL Set ID aa395339-e57c-4ccc-bc9b-4d5c4a18eeca
Established class (EPC) Angiotensin 2 Receptor Blocker
Mechanism of action Angiotensin 2 Receptor Antagonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2017-05-25
Route ORAL
Dosage form TABLET, FILM COATED
Substance OLMESARTAN MEDOXOMIL
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 50090-4451-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 50090-4451-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

📖 What it is MedlinePlus · NLM

Olmesartan is used alone or in combination with other medications to treat high blood pressure in adults and children 6 years of age and older. Olmesartan is in a class of medications called angiotensin II receptor antagonists. It works by blocking the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart dise...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Olmesartan is used to treat high blood pressure (hypertension) in adults and in kids as young as six years old. It works by relaxing your blood vessels so your heart doesn't have t...
  • No — this is one of the most important things to know about olmesartan. It can cause very serious harm to an unborn baby, including kidney failure and even death, especially after...
  • Can I take this if I'm pregnant or trying to get pregnant?
  • Dizziness is the most commonly reported side effect — it happens in about 3 out of 100 people in clinical trials. It's most likely when you first start the medicine, especially if...
📖 Read our full Olmesartan guide →
1
Nutrient depletion considerations

Olmesartan Medoxomil may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Olmesartan Medoxomil nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $0.2000 $18.00 / 90 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
50090-4451-01 You're viewing this 90 TABLET, FILM COATED in 1 BOTTLE 2019-08-05 — Active
50090-4451-00 50090-4451-0 Main listing 30 TABLET, FILM COATED in 1 BOTTLE 2019-08-05 — Active

You're viewing the largest of 2 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This is a 90-count package — 90 tablet, film coated in 1 bottle.
How does this package differ from NDC 50090-4451-00?
Both are Olmesartan Medoxomil 40 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 90-count one, while NDC 50090-4451-00 is the 30 tablets package.
What NDC number is used to bill for this package of Olmesartan Medoxomil 40 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
olmesartan medoxomil 40 mg 16729-0322-10 Accord 30 tablets $0.110 AB Availability likely —
Olmesartan Medoxomil 40 mg 00527-2427-32 Lannett 30 tablets $0.111 AB Availability likely —
Olmesartan Medoxomil 40 mg 31722-0854-30 Camber 30 tablets $0.111 AB Availability likely —
Olmesartan medoxomil 40 mg 33342-0180-07 Macleods 30 tablets $0.111 AB Availability likely —
Olmesartan Medoxomil 40 mg 43547-0301-03 Solco 30 tablets $0.111 AB Availability likely —
olmesartan medoxomil 40 mg 50228-0341-10 ScieGen 1000 tablets $0.111 AB Availability likely —
Olmesartan Medoxomil 40 mg 64980-0603-03 Rising 30 tablets $0.111 AB Availability likely —
Olmesartan medoxomil 40 mg 72205-0167-30 Novadoz 30 tablets $0.111 AB Availability likely —
Olmesartan Medoxomil 40 mg 72241-0080-04 Modavar 90 tablets $0.111 AB Availability likely —
Olmesartan Medoxomil 40 mg 72303-0850-01 HEC 30 tablets $0.111 AB Availability likely —
Olmesartan Medoxomil 40 mg 82009-0075-90 QUALLENT 90 tablets $0.111 AB Availability likely —
Olmesartan Medoxomil 40 mg 70756-0810-30 Lifestar 30 tablets $0.133 AB FDA listed —
Benicar 40 mg 00713-0862-30 Cosette 30 tablets $17.242 AB Availability likely —
Benicar 40 mg 00713-0942-30 Cosette 30 tablets $17.242 AB Availability likely —
Olmesartan Medoxomil 40 mg 42571-0203-05 Micro 500 tablets — — Discontinued —
Olmesartan Medoxomil 40 mg 46708-0133-10 Alembic 100 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 49252-0067-10 Inventia 30 tablets — AB FDA listed —
olmesartan medoxomil 40 mg 50090-3487-00 A-S 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 50090-3655-00 A-S 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mgthis 50090-4451-01 A-S 90 tablets — AB FDA listed —
Olmesartan medoxomil 40 mg 50090-6632-00 A-S 30 tablets — AB FDA listed —
Olmesartan medoxomil 40 mg 50090-6633-00 A-S 90 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 50090-7087-00 A-S 90 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 50090-7680-00 A-S 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 50090-7681-00 A-S 90 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 50090-7810-00 A-S 90 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 50090-7979-00 A-S 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 50090-7980-00 A-S 90 tablets — AB FDA listed —
olmesartan medoxomil 40 mg 51407-0199-30 Golden 30 tablets — AB FDA listed —
olmesartan medoxomil 40 mg 59746-0466-01 Jubilant 100 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 60290-0011-01 Umedica 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 62135-0882-30 Chartwell 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 62332-0133-10 Alembic 100 tablets — AB FDA listed —
olmesartan medoxomil 40 mg 63629-8524-01 Bryant 90 tablets — AB FDA listed —
olmesartan medoxomil 40 mg 63629-8525-01 Bryant 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 65862-0743-01 Aurobindo 100 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 67877-0447-05 Ascend 500 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 68462-0438-10 Glenmark 1000 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 70518-1345-00 REMEDYREPACK 90 tablets — AB FDA listed —
olmesartan medoxomil 40 mg 70518-4053-00 REMEDYREPACK 90 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 71205-0174-30 Proficient 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 71205-0459-30 Proficient 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 71209-0081-01 Cadila 30 tablets — AB FDA listed —
olmesartan medoxomil 40 mg 71335-0817-01 Bryant 30 tablets — AB Discontinued —
Olmesartan Medoxomil 40 mg 71335-2362-01 Bryant 30 tablets — AB FDA listed —
olmesartan medoxomil 40 mg 71335-2380-01 Bryant 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 71335-2605-01 Bryant 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 71335-2749-01 Bryant 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 72189-0138-30 direct 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 72189-0549-30 Direct_Rx 30 tablets — AB FDA listed —
Olmesartan Medoxomil 40 mg 72189-0660-30 Direct_Rx 30 tablets — AB FDA listed —
Olmesartan medoxomil 40 mg 72603-0952-01 NorthStar 30 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2017
On the market since
May 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Olmesartan inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerA-S Medication Solutions
Application holderGLENMARK PHARMACEUTICALS LTD
FDA applicationANDA203281 (ANDA)
Labeler code50090
First marketedMay 2017
Product typeHuman Prescription Drug
Portfolio2,813 products on file

More NDCs from A-S Medication Solutions labeler code 50090

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Olmesartan Medoxomil — the program that covers self-administered drugs. 14 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Olmesartan Medoxomil. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$18.95M
Claims incl. refills
1M
Beneficiaries
847.8K
Spend / beneficiary
$22.35
Spend / claim
$18.14
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by A-S Medication Solutions. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 30 tablets (50090-4451-00). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
A-S Medication Solutions is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 50090-4447-00 · A-S 50090-4452-00 · A-S →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.